Sign Out
Severe Eosinophilic Asthma: NUCALA is indicated as an add-on maintenance treatment for patients aged 12 years old and older with severe eosinophilic asthma who: have at least two exacerbations in the preceding 12 months on current standard of care (high doses of inhaled corticosteroids plus additional maintenance treatment) and/or requirement for treatment with systemic corticosteroids, and; have a blood eosinophil count of ≥150 cells/μL (0.15 GI/L) at initiation of treatment with NUCALA OR ≥300 cells/μL (0.3 GI/L) in the past 12 months.
NUCALA is not indicated for other eosinophilic conditions or for relief of acute bronchospasm or status asthmaticus (see Precautions).
Eosinophilic Granulomatosis with Polyangiitis (EGPA): NUCALA is indicated as add-on treatment for relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over.
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
Continue with Google